Prudential Financial Inc. boosted its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 154.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 562,867 shares of the medical instruments supplier’s stock after buying an additional 341,575 shares during the period. Prudential Financial Inc.’s holdings in OraSure Technologies were worth $7,278,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. A.R.T. Advisors LLC boosted its position in OraSure Technologies by 1.8% in the fourth quarter. A.R.T. Advisors LLC now owns 40,500 shares of the medical instruments supplier’s stock worth $355,000 after buying an additional 700 shares during the last quarter. Private Advisor Group LLC boosted its position in OraSure Technologies by 7.1% in the first quarter. Private Advisor Group LLC now owns 10,923 shares of the medical instruments supplier’s stock worth $135,000 after buying an additional 723 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its position in OraSure Technologies by 5.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 19,000 shares of the medical instruments supplier’s stock worth $167,000 after buying an additional 1,000 shares during the last quarter. Campbell & CO Investment Adviser LLC boosted its position in OraSure Technologies by 27.3% in the first quarter. Campbell & CO Investment Adviser LLC now owns 18,890 shares of the medical instruments supplier’s stock worth $244,000 after buying an additional 4,048 shares during the last quarter. Finally, UBS Asset Management Americas Inc. boosted its position in OraSure Technologies by 43.5% in the first quarter. UBS Asset Management Americas Inc. now owns 30,996 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 9,400 shares during the last quarter. Institutional investors own 88.02% of the company’s stock.

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

OraSure Technologies, Inc. (NASDAQ OSUR) opened at 14.94 on Friday. The stock has a market cap of $862.96 million, a PE ratio of 28.62 and a beta of 1.60. The firm’s 50-day moving average price is $14.85 and its 200-day moving average price is $11.52. OraSure Technologies, Inc. has a 52 week low of $5.57 and a 52 week high of $15.90.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, May 3rd. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.04. The business had revenue of $32.55 million for the quarter, compared to analysts’ expectations of $31.19 million. OraSure Technologies had a return on equity of 16.06% and a net margin of 22.57%. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.04 EPS. Equities analysts predict that OraSure Technologies, Inc. will post $0.42 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Prudential Financial Inc. Has $7.28 Million Position in OraSure Technologies, Inc. (OSUR)” was published by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/prudential-financial-inc-has-7-28-million-position-in-orasure-technologies-inc-osur/1372118.html.

A number of research analysts have recently commented on the company. Zacks Investment Research cut OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, April 12th. Jefferies Group LLC raised their target price on OraSure Technologies from $12.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, May 4th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $12.04.

In other OraSure Technologies news, Director Michael Celano sold 44,962 shares of the stock in a transaction on Friday, May 5th. The stock was sold at an average price of $14.95, for a total transaction of $672,181.90. Following the sale, the director now owns 38,117 shares of the company’s stock, valued at approximately $569,849.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Mark L. Kuna sold 36,413 shares of the stock in a transaction on Monday, May 8th. The shares were sold at an average price of $15.11, for a total value of $550,200.43. Following the sale, the senior vice president now directly owns 92,904 shares in the company, valued at approximately $1,403,779.44. The disclosure for this sale can be found here. Insiders have sold a total of 929,859 shares of company stock worth $13,926,644 in the last ninety days. Insiders own 7.80% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.